



**SERES**  
THERAPEUTICS™

## Seres Therapeutics to Present at Two Upcoming March Conferences

March 9, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 9, 2018-- [Seres Therapeutics, Inc.](http://www.businesswire.com/news/home/20180309005031/en/) (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences:

- **The 38<sup>th</sup> Annual Cowen & Co. Health Care Conference:** a corporate overview will be presented on Wednesday, March 14 at 10:40 a.m. ET in Boston, MA.
- **Oppenheimer's 28<sup>th</sup> Annual Healthcare Conference:** a corporate overview will be presented on Tuesday, March 20 at 10:20 a.m. ET in New York, NY.

A live audio webcast of each presentation will be available under the "Investors and Media" section of Seres' website. A replay of each presentation will become available approximately one hour after the event and will be archived for 21 days.

### About Seres Therapeutics

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres' lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent *C. difficile* infection. Seres' clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis and has obtained Orphan Drug designation for pediatric Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary *C. difficile* infection and is developing SER-401 to enhance the efficacy of checkpoint inhibitors in patients with certain tumors. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com). Follow us on Twitter [@SeresTx](https://twitter.com/SeresTx).



View source version on businesswire.com: <http://www.businesswire.com/news/home/20180309005031/en/>

Source: Seres Therapeutics, Inc.

Seres Therapeutics  
Carlo Tanzi, Ph.D., 617-203-3467  
Vice President, Investor Relations and Corporate Communications  
[ctanzi@serestherapeutics.com](mailto:ctanzi@serestherapeutics.com)